Display options
Cite
Shah SR, Iqbal SM, Alweis R, et al. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol. 2018;12(1):45-52doi: 10.1080/17512433.2019.1552830.
Shah, S. R., Iqbal, S. M., Alweis, R., & Roark, S. (2019). A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert review of clinical pharmacology, 12(1), 45-52. https://doi.org/10.1080/17512433.2019.1552830
Shah, Syed Raza, et al. "A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs." Expert review of clinical pharmacology vol. 12,1 (2019): 45-52. doi: https://doi.org/10.1080/17512433.2019.1552830
Shah SR, Iqbal SM, Alweis R, Roark S. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol. 2019 Jan;12(1):45-52. doi: 10.1080/17512433.2019.1552830. Epub 2018 Dec 03. PMID: 30488734.
Copy Download .nbib Format: NLM
Share it on

Expert Rev Clin Pharmacol. 2019 Jan;12(1):45-52. doi: 10.1080/17512433.2019.1552830. Epub 2018 Dec 03.

A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs.

Expert review of clinical pharmacology

Syed Raza Shah, Sana Muhammad Iqbal, Richard Alweis, Steven Roark

Affiliations

  1. a North Florida Regional Medical Center , University of Central Florida (Gainesville) , Gainesville , FL , USA.
  2. b Department of Medicine , Dow University of Health Sciences (DUHS) , Karachi , Pakistan.
  3. c Department of Medicine , Rochester Regional Health System , Rochester , NY , USA.
  4. d North Florida Regional Medical Center, The Cardiac and Vascular Institute , University of Central Florida (Gainesville) , Gainesville , FL , USA.

PMID: 30488734 DOI: 10.1080/17512433.2019.1552830

Abstract

INTRODUCTION: Type 2 diabetes (T2D) is an independent risk factor for heart failure (HF). With concomitant T2D and HF, recent data suggests an incremental risk of cardiovascular death and hospitalization for HF, as compared to patients with HF without T2D. Areas covered: Management of these two diseases has been a challenge for physicians. The treatment goals for HF patients in T2D are very important. They serve as the endpoint in using a specific treatment for management and treatment of T2D patients hence, decreasing mortality rates. In this review, we examine the effects of oral antidiabetic drugs on HF patients, discussing current evidence-based up-to-date management strategies and guidelines in the general population with HF and T2D. Expert commentary: Future in the management of T2D in HF patients looks bright. Augmenting data on potential cardiovascular side effects of antidiabetic drugs is valuable since millions of people are treated over many years. Newer novel drugs targeting specific signaling pathways are approaching the stages of clinical investigation. They have been a highly attractive concept for the future in the management of these patients. However, while advances in technology elucidated many aspects of these diseases, many mysteries still remain.

Keywords: Heart failure; diabetes mellitus-2; pharmacology

Substances

MeSH terms

Publication Types